FOXL2 and neoplasm: With the goal of validating the immunogenicity and effectiveness of FOXL2-targeted response, we developed a plasmid-DNA vaccine encoding murine Foxl2 that was able to reduce tumor progression in FOXL2-expressing ovarian and breast cancer models in a T cell–mediated manner.